Systemic vasculitis: A critical digest of the recent literature

Clinical and Experimental Rheumatology

Volumn 31, Issue SUPPL.75, 2013, Pages

  Talarico, R ^a   Baldini, C ^a   Della Rossa, A ^a   Carli, L ^a,b   Tani, C ^a   Bombardieri, S ^a  

^a UNIVERSITY OF PISA   (Italy)

^b UNIVERSITY OF SIENA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; AZATHIOPRINE; BOCEPREVIR; CYCLOPHOSPHAMIDE; GLUCOCORTICOID; MEPOLIZUMAB; METHOTREXATE; OMALIZUMAB; PEGINTERFERON; PREDNISOLONE; PROTEINASE INHIBITOR; RIBAVIRIN; RITUXIMAB; TELAPRIVIS; TOCILIZUMAB; TUMOR NECROSIS FACTOR ALPHA INHIBITOR; UNCLASSIFIED DRUG;

ANCA ASSOCIATED VASCULITIS; ANTIVIRAL THERAPY; AORTA ARCH SYNDROME; CLINICAL ASSESSMENT; COLOR ULTRASOUND FLOWMETRY; CRYOGLOBULINEMIA; DISEASE CLASSIFICATION; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; GIANT CELL ARTERITIS; HEPATITIS C; HISTOPATHOLOGY; HUMAN; PRIORITY JOURNAL; REVIEW; SYSTEMIC VASCULITIS; TEMPORAL ARTERY;

ANIMALS; ANTI-NEUTROPHIL CYTOPLASMIC ANTIBODY-ASSOCIATED VASCULITIS; CRYOGLOBULINEMIA; GIANT CELL ARTERITIS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; RISK FACTORS; SYSTEMIC VASCULITIS; TERMINOLOGY AS TOPIC; TREATMENT OUTCOME;

EID: 84878432571     PISSN: 0392856X     EISSN: 1593098X     Source Type: Journal    
DOI: None     Document Type: Review

References (57)

1. HELLMICH B: Update on the management of systemic vasculitis: what did we learn in 2009. Clin Exp Rheumatol 2010; 28 (Suppl. 57): 98-103.
2. TALARICO R.BALDINI C, DELLA ROSSA A et al.: Large-and small-vessel vasculitis: a critical digest of the 2010-2011 literature. Clin Exp Rheumatol 2012; 30 (Suppl. 70): S130-8
3. TRIESTE L, PALLA I, BALDINI C et al.: Systemic vasculitis: how little we know about their societal and economic burden. Clin Exp Rheumatol 2012; 30 (Suppl. 73): S154-6.
4. CARPENTER DM, MEADOR AE, ELSTAD EA, HOGAN SL, DEVELLIS RF: The impact of vasculitis on patients' social participation and friendships. Clin Exp Rheumatol 2012; 30 (Suppl. 70): S15-21.
5. JENNETTE JC, FALK RJ, BACON PA et al.: 2012 revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides. Arthritis Rheum 2013; 65: 1-11.
6. JENNETTE JC, FALK RJ, ANDRASSY K et al.: Nomenclature of systemic vasculitides. Proposal of an international consensus conference. Arthritis Rheum 1994; 37: 187-92.
7. DE MIGUEL E, ROXO A, CASTILLO C, PEITEADO D, VILLALBA A, MARTÍN-MOLA E: The utility and sensitivity of colour Doppler ultrasound in monitoring changes in giant cell arteritis. Clin Exp Rheumatol 2012; 30 (Suppl. 70): S34-8.
8. GHINOI A, PIPITONE N, NICOLINI A et al.: Large-vessel involvement in recent-onset giant cell arteritis: a case-control colour-Doppler sonography study. Rheumatology (Oxford) 2012; 51: 730-4.
9. LOOCK J, HENES J, KÖTTER I et al.: Treatment of refractory giant cell arteritis with cyclophosphamide:a retrospective analysis of 35 patients from three centres. Clin Exp Rheumatol 2012; 30 (Suppl. 70):S70-6.
10. DE BOYSSON H, BOUTEMY J, CREVEUIL C et al.: Is there a place for cyclophosphamide in the treatment of giant-cell arteritis? A case series and systematic review. Semin Arthritis Rheum 2013 Feb 27 [Epub].
11. PIPITONE N, OLIVIERI I, SALVARANI C: Recommendations of the Italian Society of Rheumatology for the treatment of the primary large-vessel vasculitis with biological agents. Clin Exp Rheumatol 2012; 30 (Suppl. 70): S139-61.
12. NISHIMOTO N, NAKAHARA H, YOSHIOHOSHINO N, MIMA T: Successful treatment of a patient with Takayasu arteritis using a humanized anti-interleukin-6 receptor antibody. Arthritis Rheum 2008; 58: 1197-200.
13. SEITZ M, REICHENBACH S, BONEL HM, ADLER S, WERMELINGER F, VILLIGER PM: Rapid induction of remission in large vessel vasculitis by IL-6 blockade. A case series. Swiss Med Wkly 2011; 141: w13156.
14. SALVARANI C, MAGNANI L, CATANOSO M et al.: Tocilizumab: a novel therapy for patients with large-vessel vasculitis. Rheumatology (Oxford) 2012; 51: 151-6.
15. LURATI A, BERTANI L, RE KA, MARRAZZA M, BOMPANE D, SCARPELLINI M: Successful treatment of a patient with giant cell vasculitis (horton arteritis) with tocilizumab a humanized anti-interleukin-6 receptor antibody. Case Rep Rheumatol 2012 Apr 3 [Epub].
16. UNIZONY S, ARIAS-URDANETA L, MILOSLAVSKY E et al.: Tocilizumab for the treatment of large-vessel vasculitis (giant cell arteritis, Takayasu arteritis) and polymyalgia rheumatica. Arthritis Care Res (Hoboken). 2012; 64: 1720-9.
17. IŞIK M, KILIÇ L, DOǦAN I, CALGÜNERI M: Tocilizumab for giant cell arteritis: an amazing result. Rheumatol Int 2012 Sep 11 [Epub].
18. SALVARANI C, MAGNANI L, CATANOSO M et al.: Tocilizumab: a novel therapy for patients with large-vessel vasculitis. Rheumatology (Oxford) 2012; 51: 151-6.
19. BRAVO MANCHEÑO B, PERIN F, GUEZ VÁZQUEZ DEL REY MDEL M, GARCÍA SÁNCHEZ A, ALCÁZAR ROMERO PP: Successful tocilizumab treatment in a child with refractory Takayasu arteritis. Pediatrics 2012; 130: e1720-4
20. BREDEMEIER M, ROCHA CM, BARBOSA MV, PITREZ EH: One-year clinical and radiological evolution of a patient with refractory Takayasu's arteritis under treatment with tocilizumab. Clin Exp Rheumatol 2012; 30 (Suppl. 70): S98-100.
21. SALVARANI C, MAGNANI L, CATANOSO MG et al.: Rescue treatment with tocilizumab for Takayasu arteritis resistant to TNF-a blockers. Clin Exp Rheumatol 2012; 30 (Suppl. 70): S90-3.
22. WATTS RA, MOONEY J, SKINNER J, SCOTT DG, MACGREGOR AJ: The contrasting epidemiology of granulomatosis with polyangiitis (Wegener's) and microscopic polyangiitis. Rheumatology (Oxford) 2012; 51: 926-31.
23. LYONS PA, RAYNER TF, TRIVEDI S et al.: Genetically distinct subsets within ANCAassociated vasculitis. N Engl J Med 2012; 367: 214-23.
24. MAHR A, KATSAHIAN S, VARET H et al.; FOR THE FRENCH VASCULITIS STUDY GROUP (FVSG) AND THE EUROPEAN VASCULITIS SOCIETY (EUVAS): Revisiting the classification of clinical phenotypes of anti-neutrophil cytoplasmic antibody-associated vasculitis: a cluster analysis. Ann Rheum Dis 2012 Dec 12 [Epub].
25. COMARMOND C, PAGNOUX C, KHELLAF M et al.: clinical characteristics and long-term followup of the 383 patients enrolled in the French Vasculitis Study Group cohort. Arthritis Rheum 2013; 65: 270-81.
26. FAURSCHOU M, WESTMAN K, RASMUSSEN N et al.: Brief Report: long-term outcome of a randomized clinical trial comparing methotrexate to cyclophosphamide for remission induction in early systemic antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum 2012; 64: 3472-7.
27. HENES JC, HENES M, VON WOLFF M, SCHMALZING M, KÖTTER I, LAWRENZ B: Fertility preservation in women with vasculitis: experiences from the FertiPROTEKT network. Clin Exp Rheumatol 2012; 30 (Suppl. 70): S53-6.
28. GUERRY MJ, BROGAN P, BRUCE IN et al.: Recommendations for the use of rituximab in anti-neutrophil cytoplasm antibody-associated vasculitis. Rheumatology (Oxford) 2012; 51: 634-43.
29. SMITH RM, JONES RB, GUERRY MJ et al.: Rituximab for remission maintenance in relapsing antineutrophil cytoplasmic antibodyassociated vasculitis. Arthritis Rheum 2012 ; 64: 3760-9.
30. ROUBAUD-BAUDRON C, PAGNOUX C, MÉAUX-RUAULT N et al.: Rituximab maintenance therapy for granulomatosis with polyangiitis and microscopic polyangiitis. J Rheumatol 2012; 39: 125-30.
31. CARTIN-CEBA R, GOLBIN JM, KEOGH KA et al.: Rituximab for remission induction and maintenance in refractory granulomatosis with polyangiitis (Wegener's): ten-year experience at a single center. Arthritis Rheum 2012; 64: 3770-8
32. HOLLE JU, DUBRAU C, HERLYN K et al: Rituximab for refractory granulomatosis with polyangiitis (Wegener's granulomatosis): comparison of efficacy in granulomatous versus vasculitic manifestations. Ann Rheum Dis 2012; 71: 327-33.
33. PULLERITS R, LJEVAK M, VIKGREN J, BOKAREWA M: Off-trial evaluation of the B cell-targeting treatment in the refractory cases of antineutrophil cytoplasmic antibodies (ANCA)-associated vasculitis: long-term follow-up from a single centre. Scand J Immunol 2012; 76: 411-20.
34. BASLUND B, WIENCKE AK, RASMUSSEN N, FAURSCHOU M, TOFT PB: Treatment of orbital inflammation with rituximab in Wegener's granulomatosis. Clin Exp Rheumatol 2012; 30 (Suppl. 70): S7-10.
35. BALDINI C, GALLO A, PEREZ P, MOSCA M, ALEVIZOS I, BOMBARDIERI S: Saliva as an ideal milieu for emerging diagnostic approaches in primary SjÖgren's syndrome. Clin Exp Rheumatol 2012; 30: 785-90.
36. KHOURY P, ZAGALLO P, TALAR-WILLIAMS C et al.: Serum biomarkers are similar in Churg-Strauss syndrome and hypereosinophilic syndrome. Allergy 2012; 67: 1149-56.
37. MARTINI D, BALDINI C, LATORRE M et al.: Future prospects for salivary proteomics in rheumatology: the example of eosinophil granulomatosis with polyangiitis. Clin Exp Rheumatol 2012; 30: 810-1.
38. GUILLEVIN L: Treatment of Churg-Strauss syndrome: Options for the future Clin Exp Rheumatol 2012; 30 (Suppl. 70): S-6.
39. LATORRE M, BALDINI C, SECCIA V et al.: Omalizumab: a novel steroid sparing agent in eosinophilic granulomatosis with polyangiitis? Clin Exp Rheumatol 2013: 31 (Suppl. 91): S91.
40. HERRMANN K, GROSS WL, MOOSIG F: Extended follow-up after stopping mepolizumab in relapsing/refractory Churg-Strauss syndrome. Clin Exp Rheumatol 2012; 30 (Suppl. 70): S62-5.
41. CORREN J: Inhibition of interleukin-5 for the treatment of eosinophilic diseases. Discov Med 2012; 13: 305-12.
42. MOLFINO NA, GOSSAGE D, KOLBECK R, PARKER JM, GEBA GP: Molecular and clinical rationale for therapeutic targeting of interleukin-5 and its receptor. Clin Exp Allergy 2012; 42: 712-37.
43. ALBA MA. FLORES-SUÁREZ LP: Seven clinical conundrums in the treatment of anca-associated vasculitis. Clin Exp Rheumatol 2013; 31 (Suppl. 75): S74-S83.
44. DE VITA S, SOLDANO F, ISOLA M et al.: Preliminary classification criteria for the cryoglobulinaemic vasculitis. Ann Rheum Dis 2011; 70: 1183-90.
45. QUARTUCCIO L, ISOLA M, CORAZZA L et al.: Performance of the preliminary classification criteria for cryoglobulinaemic vasculitis and clinical manifestations in hepatitis C virusunrelated cryoglobulinaemic vasculitis. Clin Exp Rheumatol 2012; 30: S48-S52.
46. LAMPRECHT P: Crioglobulinaemic vasculitis: new aspects. Clin Exp Rheumatol 2012; 30 (Suppl. 70): S3-S5.
47. VISENTINI M, CONTI V, CRISTOFOLETTI C et al.: Clonal expansion and functional exhaustion of monoclonal marginal zone B cells in mixed cryoglobulinemia: The yin and yang of HCV-driven lymphoproliferation and autoimmunity. Autoimmun Rev 2013; 12: 430-5.
48. TERRIER B CACOUB P: Cryoglobulinemic vasculitis: an update. Curr Opin Rheumatol 2013; 25: 10-8.
49. ANTONELLI A, FALLAHI P, FERRARI SM et al.: Chemokine (CXC motif) ligand 9 serum levels in mixed cryoglobulinaemia are associated with circulating levels of IFN-gamma and TNF-alpha. Clin Exp Rheumatol 2012; 30: 864-70.
50. ANTONELLI A, FERRI C, FERRARI SM et al.: The presence of autoimmune thyroiditis in mixed cryoglobulinemia patients is associated with high levels of circulating interleukin-6, but not of tumor necrosis factor-alpha. Clin Exp Rheumatol 2011; 29 (Suppl. 64): S17-S22.
51. TERRIER B, JEHAN F, MUNTEANU M et al.: Low 25-hydroxyvitamin D serum levels correlate with the presence of extra-hepatic manifestations in chronic hepatitis C virus infection. Rheumatology (Oxford) 2012; 5: 2083-90.
52. PIETROGRANDE M, DE VITA S, ZIGNEGO AL et al.: Recommendations for the management of mixed cryoglobulinemia syndrome in hepatitis c virus-infected patients. Autoimmun Rev 2011; 10: 444-54.
53. DE VITA S, QUARTUCCIO L, ISOLA M et al.: A randomized controlled trial of Rituximab for the treatment of severe cryoglobulinemic vasculitis. Arthritis Rheum 2012; 64: 843-53.
54. SNELLER MC, HU Z, LANGFORD CA: A randomized controlled trial of rituximab following failure of antiviral therapy for hepatitis C virus-associated cryoglobulinemic vasculitis. Arthritis Rheum 2012; 64: 835-42.
55. FERRI C, CACOUB P, MAZZARO C et al.: Treatment with rituximab in patients with mixed cryoglobulinemia syndrome: Results of multicenter cohort study and review of the literature. Autoimmun Rev 2011; 11: 48-55.
56. TERRIER B, SEMOUN O, SAADOUN D et al.: Prognostic factors in patients with hepatitis C infection and systemic vasculitis. Arthritis Rheum 2011; 63: 1748-57.
57. MAZZARO C, MONTI G, SACCARDO F et al.: Efficacy and safety of peginterferon alfa-2b plus ribavirin for HCV-positive mixed cryoglobulinemia: A multicentre open-label study. Clin Exp Rheumatol 2011; 29: 933-41.